RENX.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 11:35):

Stats
Today's Volume	47 266.00
Average Volume	731 993
Market Cap	39.13M
EPS	£0 ( 2024-03-27 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.830
ATR14	£0.619 (2.13%)

Renalytix AI PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Renalytix AI PLC Financials

Annual	2022
Revenue:	£3.40M
Gross Profit:	£701 000 (20.60 %)
EPS:	£-0.560

Q2	2023
Revenue:	£709 000
Gross Profit:	£257 000 (36.25 %)
EPS:	£0

Q1	2023
Revenue:	£459 000
Gross Profit:	£-43 000.00 (-9.37 %)
EPS:	£-0.110

Q4	2022
Revenue:	£518 000
Gross Profit:	£-155 000 (-29.92 %)
EPS:	£-0.00440

Financial Reports:

No articles found.

Renalytix AI PLC

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.